Can a 14-Day Anti-Inflammatory shot stop heart failure after a heart attack?
NCT ID NCT05177822
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a drug called anakinra, which reduces inflammation, can help prevent heart failure in people who have just had a heart attack. About 84 participants will receive daily injections of anakinra or a placebo for up to 14 days. The goal is to see if blocking inflammation improves heart function and exercise capacity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anakinra (Kineret), an anti-inflammatory drug
What this could lead to
If it works, this could point toward a new way to prevent heart failure after a heart attack by calming inflammation.
What could go wrong
This is a small, early-phase trial with only 84 participants, so results may not apply to everyone. The drug is given for just 14 days, and its long-term benefits are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States